Article
Phase II Trial of Sunitinib in BAC or Never-smokers with Any Lung Adenocarcinoma
Sunitinib is a new oral drug for advanced stage lung cancer. This study will determine the efficacy of sunitinib in patients with bronchoalveolar carcinoma (BAC) and in never-smokers with any type of adenocarcinoma.
Study Type: Interventional
Age/Sex Requirements: 18 years+ (None)
Sponsor: Swedish Medical Center, Pfizer
ClinicalTrials.gov Identifier: NCT00430261
Purpose: Sunitinib is a new oral drug for advanced stage lung cancer. This study will determine the efficacy of sunitinib in patients with bronchoalveolar carcinoma (BAC) and in never-smokers with any type of adenocarcinoma. Treatment will consist of 50 mg of sunitinib by mouth once a day for 4 weeks on followed by 2 weeks off for a 6-week cycle. Primary outcome measures include progression-free survival and time to progression.
Click here to learn more about this clinical trial.
